Sterility Testing Market Top Growing Segments and Future Development

According to the new market research report sterility testing market is expected to reach $941.0 Million by 2021, at a CAGR of 12.3%.

Posted on 2021-10-20 by MarketsandMarkets in Healthcare // 0 Comments

Northbrook, IL, USA, 2021-Oct-20 — /EPR Network/ — According to the new market research report sterility testing market is expected to reach USD 941.0 Million by 2021 from USD 528.0 Million in 2016, at a CAGR of 12.3% from 2016 to 2021.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=208866931

The growth of the sterility testing market can be attributed to the growth in the pharmaceutical and biotechnology industries, increase in the number of new drug launches, and increasing R&D in life science research.

On the basis of product, the Sterility Testing Market is segmented into kits and reagents, instruments, and services. The kits and reagents segment is expected to account for the largest share of the market. The large share of the kits and reagents segment can be attributed to the requirement of the repeat purchase of these products, coupled with the increasing preference for kit-based testing.

On the basis of test, the Sterility Testing Market is segmented into membrane filtration, direct inoculation, and other sterility tests. In 2016, the membrane filtration segment accounted for the largest share. The large share of this segment can primarily be attributed to rapid growth in the pharmaceutical and biotechnology end-use industry.

On the basis of application, the Sterility Testing Market is segmented into pharmaceutical and biological manufacturing, medical devices manufacturing, and others applications. In 2016, the pharmaceutical and biological manufacturing segment is expected to account for the largest share primarily due to the rapid growth in the pharma and biotech industries.

Major players in the sterility testing market include Merck KGaA (Germany), Charles River Laboratories International, Inc. (U.S.), bioMérieux SA (France), SGS S.A. (Switzerland), Sartorius AG (Germany), WuXi AppTec (China), Nelson Laboratories (U.S.), Danaher Corporation (U.S.), Pacific Biolabs (U.S.), Toxikon Corporation (U.S.), and Thermo Fisher Scientific, Inc. (U.S.).

Merck KGaA (Germany) dominated the sterility testing market in 2015. The company’s dominance in the market can be attributed to its robust product portfolio and strong geographic presence. The company focuses on organic as well as inorganic growth strategies for enhancing its market position. In September 2016, the company launched its Steritest Symbio Pump systems to enhance its product portfolio and increase its market presence. Furthermore, the company was focused on inorganic growth strategies. In November 2015, Merck KGaA acquired Sigma-Aldrich Corporation (U.S.); this acquisition helped the company strengthen its sterility testing product portfolio.

Charles River Laboratories International, Inc. (U.S.) held the second position in the sterility testing market in 2015. This can be attributed to the company’s strong sterility testing portfolio. The company adopted organic growth strategies such as mergers and acquisitions to boost its market share. In November 2015, Charles River acquired Celsis International Ltd. (U.S.). This acquisition helped the company to strengthen its microbial detection product portfolio. Also in November 2015, Charles River Laboratories acquired Oncotest GmbH (Germany), a global CRO dedicated to discovery services for oncology. This acquisition strengthened Charles River’s portfolio of target discovery & validation services and in vivo pharmacology.

Request For Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=208866931

Based on region, the global sterility testing market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). The market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). The Asian market will witness the highest growth during the forecast period, primarily due to the increasing expenditure on life science research in the region and growing trend of pharmaceutical outsourcing to Asian countries like India and China.

Matched content

Editor’s pick